KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Retained Earnings (2016 - 2025)

Historic Retained Earnings for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to -$951.8 million.

  • TherapeuticsMD's Retained Earnings rose 3.17% to -$951.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$951.8 million, marking a year-over-year increase of 3.17%. This contributed to the annual value of -$951.8 million for FY2024, which is 22.97% down from last year.
  • Latest data reveals that TherapeuticsMD reported Retained Earnings of -$951.8 million as of Q3 2025, which was up 3.17% from -$951.9 million recorded in Q2 2025.
  • Over the past 5 years, TherapeuticsMD's Retained Earnings peaked at -$918.3 million during Q1 2021, and registered a low of -$1.1 billion during Q1 2022.
  • In the last 5 years, TherapeuticsMD's Retained Earnings had a median value of -$951.8 million in 2024 and averaged -$970.1 million.
  • In the last 5 years, TherapeuticsMD's Retained Earnings crashed by 2207.42% in 2021 and then surged by 1430.55% in 2023.
  • Quarter analysis of 5 years shows TherapeuticsMD's Retained Earnings stood at -$1.1 billion in 2021, then increased by 10.65% to -$939.4 million in 2022, then fell by 1.09% to -$949.6 million in 2023, then decreased by 0.23% to -$951.8 million in 2024, then increased by 0.01% to -$951.8 million in 2025.
  • Its last three reported values are -$951.8 million in Q3 2025, -$951.9 million for Q2 2025, and -$952.5 million during Q1 2025.